ClinicalTrials.gg
RecruitingNCT06770543Updated Dec 22, 2025

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

An observational study in Primary Hypercholesterolemia or Mixed Dyslipidemia, sponsored by Novartis Pharmaceuticals. Recruiting at 4 sites in South Korea. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Hypercholesterolemia by Novartis — 5 open to participants now, 9 under way, 5 of them phase 3. Hypercholesterolemia · Novartis.

Planned enrollment
4th of 10
1,500 · median 895
Started
2025
with 3 others
Observational
10 of 36
1 open now
Registered
33rd of 36
by date

Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2025, is one of 10 observational ones, and was the 33rd registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

5 of the 36 studies in Hypercholesterolemia by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Hypercholesterolemia by Novartis, or all of them as a file.
02

Study summary

This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran sodium) in routine clinical practice for the approved indications (primary hypercholesterolemia or mixed dyslipidemia).

03

Conditions studied

  • Primary Hypercholesterolemia or Mixed Dyslipidemia

Browse trials for

Keywords

  • primary hypercholesterolemia,
  • mixed dyslipidemia
  • inclisiran
  • Leqvio
04

In context

Hypercholesterolemia Reclassified

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 1,000 across 145 observational studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.

Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will involve patients who received at least one dose of Leqvio for the treatment of primary hypercholesterolemia or mixed dyslipidemia according to the current label information in Korea.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

If a subject meets all of the following criteria, he/she can participate in this study:

  1. Adult patients(18 years or older) who have hypercholesterolemia or mixed dyslipidemia and are prescribed Leqvio® Pre-filled Syringe(inclisiran sodium) according to domestically approved product information in real clinical practice
  2. Patients who are unable to reach LDL-C target with maximum tolerated dose of statin, or patients with statin intolerance
  3. Patients who provided consent to participate in the study( form)

Exclusion criteria

Exclusion Criteria:

A subjects who meets any of the following criteria cannot participate in this study:

  1. in accordance with domestic prescribing information
  2. Patients participating in clinical trials of other drugs
  3. Patients who do not provide consent to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Inclisiran

    Patients who have been treated with inclisiran

    Other: Inclisiran

Interventions

  • OtherInclisiran

    There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.

    Also known as: Leqvio®

07

What researchers measure

Primary outcomes

  1. Incidences of adverse events/adverse drug reactions (AEs/ADRs)

    Cumulative incidences of AEs, ADRs, SAEs, Serious ADR(SADRs), Unexpected AEs, and Unexpected ADRs due to Leqvio® Pre-filled Syringe(inclisiran sodium) during the observation period \["The term "unexpected" means that it is not listed in the domestic labeling(according to health authority regulations)\]

    Time frame: up to 15 months

Secondary outcomes

  1. Change from baseline in low-density lipoprotein-cholesterol (LDL-C) and lipid profiles

    Effectiveness of Leqvio® Pre-filled Syringe (inclisiran sodium) through changes in LDL-C and lipid profiles (total cholesterol, Apolipoprotein B (ApoB), non high-density lipoprotein cholesterol (non-HDL-C), Apolipoprotein A-1 (ApoA1), High Density Lipoprotein Cholesterol (HDL-C), Lipoprotein(a) (Lp(a)) and triglyceride).

    Time frame: Baseline, Months 3, 9 and 15

  2. Impact of subjects' baseline characteristics and medication usage on cumulative incidence of AEs and SAEs

    Impact of subjects' baseline characteristics(age, gender, pregnancy, BMI, lipid profile, cardiovascular risk factors and comorbidities) and medication \& non-medication(reason for using the drug, usage period, amount of use, concomitant medications) on cumulative incidence of AEs and SAEs during the observation period.

    Time frame: up to 15months

  3. Impact of subjects' baseline characteristics and medication usage on changes from baseline in LDL-C and lipid profiles

    Impact of subjects' baseline characteristics(age, gender, pregnancy, BMI, lipid profile, cardiovascular risk factors and comorbidities) and medication \& non-medication(reason for using the drug, usage period, amount of use, concomitant medications) on the changes in LDL-C and lipid profiles after treatment compared to baseline.

    Time frame: up to 15 months

08

Study locations

4 of 4 sites recruiting
  • Novartis Investigative Site
    Yangsan, Gyeongsangnam-do 50612, South Korea
    Recruiting
  • Novartis Investigative Site
    Busan, 49241, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 04763, South Korea
    Recruiting
  • Novartis Investigative Site
    Taegu, 41944, South Korea
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2031, 64 months after the start.

Of 51 observational studies under Hypercholesterolemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 13, 2025
StartActual
Aug 13, 2025
Primary completionEst.
Jan 2, 2031
CompletionEst.
Jan 2, 2031
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06770543
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Aug 13, 2025
Primary completion
Jan 2, 2031 (estimated)
Completion
Jan 2, 2031 (estimated)
Last update
Dec 22, 2025

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion